TAS-117

DRUG2 trials

Sponsors

Yonsei University, Taiho Oncology, Inc.

Conditions

Advanced or Metastatic Solid Tumors Irrespective of Gene AlterationsAdvanced or Metastatic Solid Tumors With Germline PTEN Inactivating MutationsSolid Tumor, Adult

Phase 1

TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

TerminatedNCT04770246

Taiho Oncology, Inc.Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations

Start: 2021-03-31End: 2023-03-06Updated: 2024-09-04

Phase 2

K-BASKET, TAS-117, PI3K/AKT Gene Aberration

CompletedNCT03017521

Yonsei UniversitySolid Tumor, Adult

Start: 2017-11-21End: 2019-12-31Updated: 2021-04-22

Related Papers

Abstract CT151: Phase 2 study of TAS-117 in advanced solid tumors harboringphosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene aberrations

Cancer Research2021-07-01

Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.

2021-03-1521 citations